These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

503 related articles for article (PubMed ID: 17892945)

  • 1. Effect of genomic variation in the challenge virus on the neutralization titres of recipients of inactivated JE vaccines--report of a collaborative study on PRNT50 assays for Japanese encephalitis virus (JE) antibodies.
    Ferguson M; Johnes S; Li L; Heath A; Barrett A
    Biologicals; 2008 Mar; 36(2):111-6. PubMed ID: 17892945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protection against Japanese encephalitis virus strains representing four genotypes by passive transfer of sera raised against ChimeriVax-JE experimental vaccine.
    Beasley DW; Li L; Suderman MT; Guirakhoo F; Trent DW; Monath TP; Shope RE; Barrett AD
    Vaccine; 2004 Sep; 22(27-28):3722-6. PubMed ID: 15315852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study on the protective efficacy of SA14-14-2 attenuated Japanese encephalitis against different JE virus isolates circulating in China.
    Liu X; Yu Y; Li M; Liang G; Wang H; Jia L; Dong G
    Vaccine; 2011 Mar; 29(11):2127-30. PubMed ID: 21237278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen.
    Monath TP; Guirakhoo F; Nichols R; Yoksan S; Schrader R; Murphy C; Blum P; Woodward S; McCarthy K; Mathis D; Johnson C; Bedford P
    J Infect Dis; 2003 Oct; 188(8):1213-30. PubMed ID: 14551893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cross-protection elicited by primary and booster vaccinations against Japanese encephalitis: a two-year follow-up study.
    Erra EO; Askling HH; Yoksan S; Rombo L; Riutta J; Vene S; Lindquist L; Vapalahti O; Kantele A
    Vaccine; 2013 Dec; 32(1):119-23. PubMed ID: 24176496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of protection against Japanese encephalitis virus and JE vaccine (IXIARO(®)) induced neutralizing antibody titers.
    Van Gessel Y; Klade CS; Putnak R; Formica A; Krasaesub S; Spruth M; Cena B; Tungtaeng A; Gettayacamin M; Dewasthaly S
    Vaccine; 2011 Aug; 29(35):5925-31. PubMed ID: 21723353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term immunogenicity of the new Vero cell-derived, inactivated Japanese encephalitis virus vaccine IC51 Six and 12 month results of a multicenter follow-up phase 3 study.
    Schuller E; Jilma B; Voicu V; Golor G; Kollaritsch H; Kaltenböck A; Klade C; Tauber E
    Vaccine; 2008 Aug; 26(34):4382-6. PubMed ID: 18599165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protection of SA14-14-2 live attenuated Japanese encephalitis vaccine against the wild-type JE viruses.
    Jia L; Wang Z; Yu Y
    Chin Med J (Engl); 2003 Jun; 116(6):941-3. PubMed ID: 12877812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and protective efficacy in mice of a formaldehyde-inactivated Indian strain of Japanese encephalitis virus grown in Vero cells.
    Appaiahgari MB; Vrati S
    Vaccine; 2004 Sep; 22(27-28):3669-75. PubMed ID: 15315846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy of mouse-brain inactivated Nakayama strain Japanese encephalitis vaccine--results from 30 years experience in Taiwan.
    Yang SE; Pan MJ; Tseng HF; Liau MY
    Vaccine; 2006 Mar; 24(14):2669-73. PubMed ID: 16314007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IMOJEV(®): a Yellow fever virus-based novel Japanese encephalitis vaccine.
    Appaiahgari MB; Vrati S
    Expert Rev Vaccines; 2010 Dec; 9(12):1371-84. PubMed ID: 21105774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Needle-free jet injection of small doses of Japanese encephalitis DNA and inactivated vaccine mixture induces neutralizing antibodies in miniature pigs and protects against fetal death and mummification in pregnant sows.
    Imoto J; Ishikawa T; Yamanaka A; Konishi M; Murakami K; Shibahara T; Kubo M; Lim CK; Hamano M; Takasaki T; Kurane I; Udagawa H; Mukuta Y; Konishi E
    Vaccine; 2010 Oct; 28(46):7373-80. PubMed ID: 20851083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vero cell-derived inactivated West Nile (WN) vaccine induces protective immunity against lethal WN virus infection in mice and shows a facilitated neutralizing antibody response in mice previously immunized with Japanese encephalitis vaccine.
    Lim CK; Takasaki T; Kotaki A; Kurane I
    Virology; 2008 Apr; 374(1):60-70. PubMed ID: 18221765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity of an inactivated Japanese encephalitis vaccine (JE-VAX) in humans over 20 years at USAMRIID: using PRNT50 as an endpoint for immunogenicity.
    Reisler RB; Danner DK; Gibbs PH
    Vaccine; 2010 Mar; 28(12):2436-41. PubMed ID: 20060946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Superior immunogenicity of a freeze-dried, cell culture-derived Japanese encephalitis vaccine (inactivated).
    Kikukawa A; Gomi Y; Akechi M; Onishi T; Manabe S; Namazue J; Fuke I; Ishikawa T; Okuno Y; Ueda S
    Vaccine; 2012 Mar; 30(13):2329-35. PubMed ID: 22306856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis.
    Guirakhoo F; Zhang ZX; Chambers TJ; Delagrave S; Arroyo J; Barrett AD; Monath TP
    Virology; 1999 May; 257(2):363-72. PubMed ID: 10329547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of a freeze-dried, Vero cell culture-derived, inactivated Japanese encephalitis vaccine (KD-287, ENCEVAC®) versus a mouse brain-derived inactivated Japanese encephalitis vaccine in children: a phase III, multicenter, double-blinded, randomized trial.
    Yun KW; Lee HJ; Kang JH; Eun BW; Kim YJ; Kim KH; Kim NH; Hong YJ; Kim DH; Kim HM; Cha SH
    BMC Infect Dis; 2015 Jan; 15():7. PubMed ID: 25567119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancing the utility of a prM/E-expressing chimeric vaccine for Japanese encephalitis by addition of the JEV NS1 gene.
    Ishikawa T; Wang G; Widman DG; Infante E; Winkelmann ER; Bourne N; Mason PW
    Vaccine; 2011 Oct; 29(43):7444-55. PubMed ID: 21798299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Japanese encephalitis protein vaccine candidates expressing neutralizing epitope and M.T hsp70 induce virus-specific memory B cells and long-lasting antibodies in swine.
    Fei-fei G; Jian W; Feng X; Li-ping S; Quan-yun S; Jin-ping Z; Pu-yan C; Pei-hong L
    Vaccine; 2008 Oct; 26(44):5590-4. PubMed ID: 18761388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recommendations for use of a booster dose of inactivated vero cell culture-derived Japanese encephalitis vaccine: advisory committee on immunization practices, 2011.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2011 May; 60(20):661-3. PubMed ID: 21617632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.